Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oncology Drug Spending By Health Plans May Rise 50% By 2010 – Medco

Executive Summary

Long-term cancer treatment with targeted oral therapies will spur a 46 percent to 53 percent surge in health plan spending on oncology drugs within the next three years, Medco predicts in its 2008 Drug Trend Report (see chart: "1Drug Spending By Health Plans: 2008-2010 Forecast")

You may also be interested in...

Prescription Drug Spending Remains Low, As Generics Continue To Dominate -Medco

OTC entries drive Rx utilization down.

WellCare Government Membership Up But Costs May Lead To Loss

WellCare anticipates a net loss in the first quarter 2008, versus net income of $25 million in the first quarter of 2007, due to higher medical expenses and costs associated with ongoing government and special committee investigations

GSK’s Promacta slated for committee review

GlaxoSmithKline's idiopathic thrombocytopenic purpura therapy Promacta will undergo a review by FDA's Oncologic Drugs Advisory Committee May 30. GSK is seeking approval for short-term, second-line use of Promacta (eltrombopag) to increase platelet counts and reduce or prevent bleeding in patients with chronic ITP. The company plans to follow up with a broader application for chronic ITP this year. Amgen's platelet producer Nplate (romiplostim) recently received ODAC support, but a major amendment has since delayed the application (1"The Pink Sheet," March 17, 2008, p. 3)...

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts